Lester Crawford, giving him two weeks to answer questions about how FDA tracks problems with drug safety, how it dealt with issues surrounding Vioxx, and whether the agency will study potential risks in similar drugs.
The Food and Drug Administration silenced one of its drug experts who raised safety concerns weeks before Merck amp; Co. yanked the blockbuster drug Vioxx due to increased risks for heart attack and strokes, the chairman of the Senate Finance Committee said Thursday.
For five days Merck had been struggling with what to do with frightening new data that showed that long-term use of their
